A SINGLE-MASKED, RANDOMIZED, CONTROLLED, PARALLEL GROUP, PHASE 3 CLINICAL TRIAL OF RETINAL GENE THERAPY FOR CHOROIDEREMIA USING AN ADENO-ASSOCIATED VIRAL VECTOR (AAV2) ENCODING RAB ESCORT PROTEIN 1 (REP1)

Registry ID

NSR-REP-01

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

NIGHTSTARX LTD

Last update

2016-05-06

Conditions

• CHOROIDEREMIA

Related clinical trials

• A LONG-TERM FOLLOW-UP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RETINAL GENE THERAPY IN SUBJECTS WITH CHOROIDEREMIA TREATED PREVIOUSLY WITH ADENO-ASSOCIATED VIRAL VECTOR ENCODING RAB ESCORT PROTEIN-1 (AAV2-REP1) IN AN ANTECEDENT STUDY
• AN OPEN LABEL CLINICAL TRIAL OF RETINAL GENE THERAPY FOR CHOROIDEREMIA USING AN ADENO-ASSOCIATED VIRAL VECTOR (AAV2) ENCODING RAB-ESCORT PROTEIN-1 (REP-1)

View on source registry